Canopy Growth Corp Announces Partnership with The Canadian

A company that makes it their mission to have a postive impact on their community will thrive.

One way for cannabis companies to shake the stigma associated with the industry is to be socially conscious and philanthropic.

A Leader with a Cause

This morning, Canopy Growth Corp. announced that they will be funding a first of its kind AIDS research program in conjunction with the Canadian AIDS Society. The program is designed to provide up to date information and research regarding administering patients cannabis-derived therapies and to build tools for healthcare professionals to confidently assess and prescribe cannabis to patients.

Canopy Growth will be funding the project with $200,000 to be invested over the next two years. The project will be spearheaded by the newly minted Cannabis Research Task Force. The taskforce will be responsible for developing guidelines regarding the medical use of cannabis as it applies to wellness, pain management and quality of life.

Gary Lacasse, Executive Director of the Canadian AIDS Society stated, “Our goal is to leverage our existing knowledge and expertise in both HIV and the use of cannabis for medical purposes to create a better quality of life for many Canadians facing debilitating health conditions – particularly in the area of chronic pain management.”

They will be tasked with first reviewing the current uses of cannabis derived therapies and create a statement of work for guidelines pertaining to treatment, contraindications, dosing, chronic pain, risk management and regulatory issues.

We expect to see more partnerships like this come to fruition as the industry continues to mature.

View the original content HERE.

Become a Technical420 Premium Member to learn more!

Important Investor Disclosures

This report was authored by and is property of Technical420. All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report. Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice. Any projections or other information generated by Technical420 regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results. None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment. This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation. The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals. It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction. Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks. The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission. Please contact a Financial Advisor for professional advice regarding any and all securities investments. This report is intended for informational purposes only

Source: Technical 420